TY - JOUR T1 - Proteasome inhibition enhances myeloma oncolytic reovirus therapy by suppressing monocytic anti-viral immune responses JF - medRxiv DO - 10.1101/2022.03.29.22272857 SP - 2022.03.29.22272857 AU - Ada Alice Dona AU - Enrico Caserta AU - Mahmoud Singer AU - Theophilus Tandoh AU - Lokesh Nigam AU - Janet Winchester AU - Arnab Chowdhury AU - Yinghui Zhu AU - Mariam Murtadha AU - Alex Pozhitkov AU - James F Sanchez AU - Hawa Vahed AU - Matt Coffey AU - Guido Marcucci AU - Amrita Krishnan AU - Gerard Nuovo AU - Douglas W. Sborov AU - Craig C Hofmeister AU - Flavia Pichiorri Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/04/06/2022.03.29.22272857.abstract N2 - Reovirus is an oncolytic virus with natural tropism for cancer cells. We previously showed that reovirus intravenous administration in myeloma patients was safe, but disease control associated with viral replication in the cancer cells was not observed. Here we show that ex vivo proteasome inhibitors (PIs) potentiate reovirus replication in circulating classical monocytes, increasing viral delivery to myeloma cells. We found that the anti-viral signals in monocytes primarily rely on the NF-kB activation and that this effect is impaired by the addition of PIs. Conversely, PIs improved reovirus-induced monocyte and T cell activation against cancer cells. Based on these preclinical data, we conducted a phase 1b trial of the reovirus Pelareorep together with the PI carfilzomib in 13 heavily pretreated bortezomib-resistant MM patients. Objective responses associated with reovirus active replication in MM cells, T cell activation and monocytic expansion were noted in 70% of patients.Competing Interest StatementGJN received research funding from Oncolytics Biotech Inc. MC is employed by Oncolytics Biotech Inc. CCH received research funding from BMS, Oncolytics Biotech, Sanofi, and Nektar; he received personal funds from GlaxoSmithKline, Oncopeptides, BMS, Janssen, Sanofi, and Celgene for advisory board participation, and patent-related funds from Recursion Pharmaceuticals. DWS received personal funds for consultation and advisory board participation from Sanofi, Janssen, SkylineDx, GlaxoSmithKline, Legend Biotech and Amgen. All other authors are without relevant conflicts of interest.Clinical TrialNCT02101944Funding StatementNational Cancer Institute of the National Institutes of Health grant UM1CA186691-06 (PI Taofeek Owonikoko), with the Cancer Therapy Evaluation Program (CTEP) providing Pelareorep (Reolysin). National Cancer Institute grant R01CA194742 (CCH, DWS, AD, & FP). The content is solely the responsibility of the authors and does not represent the official views of the National Cancer Institute or the National Institutes of Health. The manuscript was shared with the NCI at NCICTEPpubs{at}mail.nih.gov and pio{at}ctep.nci.nih.gov. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB of the Ohio State University Cancer Institutional Review Board gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors ER -